ViroPharma
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), ViroPharma missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue contracted significantly and GAAP earnings per share shrank to a loss.
Margins shrank across the board.
Revenue details
ViroPharma recorded revenue of $91.0 million. The 14 analysts polled by S&P Capital IQ looked for a top line of $99.2 million on the same basis. GAAP reported sales were 36% lower than the prior-year quarter's $143.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.10. The seven earnings estimates compiled by S&P Capital IQ averaged $0.13 per share. GAAP EPS were -$0.07 for Q3 against $0.35 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 76.3%, 960 basis points worse than the prior-year quarter. Operating margin was -4.6%, 4,730 basis points worse than the prior-year quarter. Net margin was -5.0%, 2,480 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $116.4 million. On the bottom line, the average EPS estimate is $0.20.
Next year's average estimate for revenue is $446.4 million. The average EPS estimate is $0.80.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,205 members out of 1,247 rating the stock outperform, and 42 members rating it underperform. Among 311 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 302 give ViroPharma a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $32.82.
- Add ViroPharma to My Watchlist.
